Over 30% of primary prostate cancers contain a consensus deletion of an approximately 800 kb locus on chromosome 6q15.1. The MAP3K7 gene, which encodes TGF-Ǫ Activated Kinase-1 (Tak1), is a putative prostate tumor suppressor gene within this region whose precise function remains obscure. In this study, we investigated the role of Tak1 in human and murine prostate cancers. In 50 well-characterized human cancer specimens, we found that Tak1 expression was progressively lost with increasing Gleason grade, both within each cancer and across all cancers. In murine prostate stem cells and Tak1-deficient prostatic epithelial cells, Tak1 loss increased proliferation, migration, and invasion. When prostate stem cells attenuated for Tak1 were engrafted with fetal urogenital mesenchyme, the histopathology of the grafts reflected the natural history of prostate cancer leading from prostatic intraepithelial neoplasia to invasive carcinoma. In the grafts containing Tak1-suppressed prostate stem cells, p38 and JNK activity was attenuated and proliferation was increased. Together, our findings functionally validate the proposed tumor suppressor role of Tak1 in prostate cancer.
Introduction
Chromosome 6q14-21 is frequently deleted in the genome of prostate cancer (1) although specific prostate tumor suppressor genes have not been identified in this region. Recently, Liu et al. using SNP arrays identified an 870 kb consensus deletion located on chromosome 6q15 (2) . The frequency of 6q15 deletion was significantly higher in tumors with Gleason score 8 (12 of 17 tumors, 71%) than in those of Gleason scores 7 (9 of 38 tumors, 24%). The association between 6q15 copy number changes and Gleason score was stronger than the association of any other common recurrent DNA copy number change identified, including PTEN, which had a similar prevalence of deletion but lower association with Gleason score.
The majority of 6q15 deletions were hemizygous.
Five genes are deleted in the 6q15 consensus region; MDN1, CASP8AP2, CX62, BACH2, and MAP3K7, as well as one pseudogene (LOC644269). Four of these five genes are either required for cell viability [MDN1 (3) and CASP8AP2 (4, 5) ] or are expressed in a tissuespecific manner that does not include the prostate [CX62 (6) and BACH2 (7) ]. Therefore, these four genes are not good candidate prostate tumor suppressor genes.
The MAP3K7 gene encodes TGF-β activated kinase-1 (Tak1), a member of the MEKK family, which was identified for its role in non-canonical TGF-β receptor signaling through the MAP kinase pathway leading to JNK and p38 activation (8) . Tak1 is also a downstream signaling molecule of numerous other pathways, including IL-1(9), TNF (10), Wnt/β-catenin (11) , and Toll receptor (12) pathways. Cytokines such as TNFα and IL-1 activate signaling cascades in inflammatory cells that involve MAP kinase signaling and lead to activation of NF-kB and/or 5 June-N-terminal Kinase (JNK) (13) . Tak1 has been found to be a central mediator of these signaling pathways (10, 12) . Recent work has demonstrated a role for Tak1 in the activation of Snf1/AMP-activated protein kinase (AMPK) (14, 15) and in the activation of LKB1 (16) .
These studies demonstrate an important regulatory role of Tak1 in integrating multiple signaling pathways and suggest that MAP3K7 could function as a tumor suppressor.
Together, our previous genetic data that demonstrate frequent hemizygous deletion of MAP3K7 in prostate cancer and the known roles of Tak1 in integrating and regulating multiple signaling pathways important for prostate growth and differentiation support a role for Tak1 as a prostate tumor suppressor. However, the functional role of Tak1 as a prostate tumor suppressor has not been reported. 
Materials and Methods

Human Samples
Formalin-fixed paraffin-embedded prostate tissues were from men who underwent radical prostatectomy at Stanford University Medical Center between 1983 and 1998. There is no information on race in this cohort. Historically during this period greater than 95% of men who underwent prostatectomy at Stanford University were Caucasian. This study received Institutional Review Board approval. Fifty prostate cancers were sectioned at Stanford University. The detailed information of staining and scoring TAK1 protein is described in Supplemental Materials and Methods and Supplementary Table 1.
Cell Culture
The isolation and characterization of the adult mouse prostatic stem/progenitor cell line, WFU3 was described previously in detail (17, 18) . Tak1 lox/lox mouse prostate epithelial cells (MPECs) were isolated from the prostate of 8-week Tak1 lox/lox male mice as previously described (18) . Generation and genotyping of Tak1 lox/lox mice were described previously in detail (12 Table 2 .
Lentivirus-mediated Gene Knockdown
The shRNA plasmids, pBS/U6/Map3k7 (target sequence GGCAGTGTTCGAACAACATT) and pBS/U6/shControl (GGGCCATGGCACGTAC GGCAAG) were constructed based on previously published work (20) . The shRNA targeting sequences were cloned into a modified LentLox3.7 lentivirus vector (21, 22) . Methods to generate lentivirus were described previously (23) . Infection efficiency was detected by EGFP expression. Individual clones were isolated using cloning cylinders after cells were grown at clonogenic density.
Cell Growth Assay
Mouse shTak1 or shControl cells were inoculated onto 6- 
Immunoblots
Protein lyastes from cells or tissues were collected and quantified by following standard protocols. Approximately 25 μg of lysate were used for immunoblots. Protein resolving, membrane transferring, and blocking were performed following standard protocols. The membranes were incubated with primary antibodies for Tak1 (1:1,000,), P-JNK (1:1,000), JNK (1:2,000), P-p65 (1:1,000), p65 (1:2,000), P-p38 (1:2,000), p38 (1:1,000), Į-tubulin 
Invasion Assay
Invasion assays were performed using BD BioCoat TM Matrigel TM invasion chambers (BD Biosciences) following the manufacturer's instructions. The detailed material and methods were described in Supplemental Materials and Methods.
Tissue Recombination
All procedures with animals were approved by the Wake Forest University Institutional Animal Care and Use Committee. Prostate tissue recombination was performed as described previously (17, (24) (25) (26) . The detailed materials and methods are described in Supplemental Material and Methods.
on May 
Statistical Methods
Repeated measures ANOVA was performed that accounted for the within-clone correlation of repeated measures due to replicates or time points using a mixed-effects regression modeling approach to test for differences by group and clone. ANOVA and t-tests were used for analysis of cross-sectional data. More detailed information is described in Supplemental Materials and Methods. A two-sided p-value < 0.05 was considered statistically significant. All analyses were performed using SAS v9.2 (SAS Institute Inc., Cary, NC) and Stata v10.1 (StataCorp, College Station, TX). Fig. S2A ). We analyzed the methylation of MAP3K7 promoter region by using bisulfite sequencing method. We found CpG islands in the promoter regions of DU145 were hypermethylated (Supplementary Fig. S2A and S2B ), but not in LnCaP or PC3 cells.
RESULTS
Tak1 Expression Is Lost in High Grade Human Prostate Cancer
Deficiency of Tak1 Altered Growth of Mouse Prostate Cells In Vitro
To model the role of Tak1 in prostate growth and development both in vitro and in vivo, we used a novel mouse prostate stem cell developmental model that we described (17) . In this model, a stem cell line we developed (WFU3) (18) can be grown and manipulated in vitro and subsequently used for in vivo analysis of prostate glandular development. We explored the expression of the five genes, Map3k7, Casp8ap2, Gja10, Bach2, and Mdn1, whose homologs are deleted in prostate cancer at the human 6q15 locus, in the syntenic region of the mouse Table 2 ). Reverse transcription PCR of total RNA isolated from semi-confluent WFU3 cells is shown in Figure 2A . Negligible gene expression was detected for Bach2, Gja10 (the mouse CX22 homolog) and Mdn1. Both Map3k7 and Casp8ap2 exhibited robust expression. Given the recent literature that indicates an essential role of Casp8ap2 in histone gene expression (4, 5), we reasoned that the possibility of CASP8AP2 being a tumor suppressor gene was less likely than for MAP3K7. Therefore, the role of Tak1 as a tumor suppressor was explored further.
We knocked down the expression of Tak1 in WFU3 cells by infection with Tak1 shRNA lentivirus (shTak1). ShRNA lentivirus (shControl) that does not significantly recognize the sequence of any known gene, was used as control. To remove the uninfected cells from the pooled cell populations, we isolated individual clonal populations with high E-GFP expression. Immunoblots probed for Tak1 expression demonstrated that shTak1 shut down the expression of Tak1 protein to nearly undetectable levels (Fig. 2B) . We assessed cell growth in presence or absence of Tak1. Interestingly, we found that shTak1 WFU3 cells exhibited faster kinetics of growth under monolayer conditions (Fig. 2C ) and greater clonogenic survival relative to shControl cells (Fig. 2D) . In parallel to these studies with WFU3 progenitor cells, we also generated mouse prostatic epithelial cells (MPECs) from Tak1 lox/lox mice (12) and deleted the floxed allele in vitro with self-deleting Cre lentivirus (19) (Fig. 2E) 
Deficiency of Tak1 Expression Promotes Cell Motility and Invasion In Vitro
During the course of generation and characterization of WFU3 cells with knockdown of Tak1, we noted a distinct morphological change in shTak1 cells relative to shControl cells. We found that shControl cells grew in clusters with extensive cell-cell junctions and presented a polygonal cobblestone-like shape (Fig. 3A) . This pattern of growth is a normal phenotype for WFU3 cells grown under these conditions. In contrast, shTak1 WFU3 cells grew in a loosely scattered pattern, with very few cell-cell junctions and an elongated spindle-like shape (Fig.   3A) . Cell-scatter assay demonstrated that more shTak1 cells underwent scattering and cell-cell disassociation compared with shControl cells ( Supplementary Fig. S3A and B) . To further evaluate the morphological difference between shTak1 and shControl cells, we labeled the cells with fluorescent phalloidin to visualize F-actin in cells growing in monolayer. shControl cells grew in clusters with F-actin staining concentrated at the cell interfaces, whereas shTak1 clones exhibited a reorganization of the F-actin away from the membrane into stress fibers with fan-shaped protruding edges (Fig. 3A) . This morphological change was suggestive of a more motile phenotype. To test the motility of the cells we performed wound healing, or scratch assays, a scratch was made in a confluent monolayer and repeat images were captured from specific locations every 10 hours. The rate of cell migration into the "wound" was determined after calculation of the distance migrated at each time point. We observed enhanced migration of shTak1 cells at every time point (Fig. 3B) . The migratory enhancement was evident for multiple clones and was reproduced in Tak1-null MPECs, relative to their floxed counterparts (Fig. 3C) . We next measured the ability of shTak1 and shControl cells to migrate through an extracellular matrix using a Matrigel Boyden Chamber assay. Knockdown of Tak1 enhanced migration through Matrigel approximately 4-fold (Fig. 3D) . In response to 
TNFα Tak1 can activate JNK/p38 or NFțB which regulate the transcription of genes involved in apoptosis, survival, motility, or inflammatory response (10, 12, 13) . We found that activation of both JNK and NFțB (p65) was attenuated in Tak1 null prostate epithelial cells upon the treatment of TNFĮ (Fig. 3E) .
Suppression of Tak1 in Prostate Stem Cells Promotes Prostate Tumorigenesis In Vivo
We hypothesized that if the in vitro alterations we observed with shTak1 cells were manifested in vivo, then hyperplastic and possibly invasive developmental abnormalities would ensue.
Three clones each of shTak1 cells and shControl cells were independently combined with UGM and grafted under the renal capsules of nude mice. For each clone, four independent grafts were prepared. After 10 weeks of in vivo growth the grafts were harvested, fixed, and sectioned for histology. The histological evaluation was done by a board certified veterinary pathologist, J. Mark Cline and by Scotrt D. Cramer. Grafts containing UGM alone exhibited small mesenchymal masses with no epithelium evident (Fig. 4A) . Grafts from shControl cells only formed benign structures (Fig. 4A and B) with complete lineage differentiation into androgen receptor (AR), CK8, and CK18 positive luminal cells, p63, CK5, and CK14 positive basal cells, and secretion of mouse dorso-lateral secretory protein (mDLP) into the lumens (Fig. 4C) . Three of the grafts from the shControl cells had small foci of benign hyperplasia (p63 and AR positive) with no evidence of nuclear atypia ( Supplementary Fig. S4 ). These results are consistent with the benign phenotype of the parental WFU3 cells that we reported previously (17) . In contrast, while all of the grafts formed from shTak1 cells had the presence of some benign glands, 80% percent showed dysplasia and/or high grade prostatic intraepithelial neoplasia (PIN) (Fig. 4A and B ( Fig. 4A and B) . The average weight of grafts formed either by shControl cells or shTak1 cells was not significantly different (Fig. 4D) . To confirm the histopathological diagnosis we stained sections with lineage-specific markers AR, CK8, CK18 (luminal cell markers), p63, CK5, and CK14 (basal cell markers) (Fig. 5) (see (27) ). Areas with morphologic features of high-grade PIN were confirmed by abundant luminal cell crowding, nuclear atypia, prominent nucleoli (arrow head in Focal areas of p63 positive clusters were also observed, which may indicate areas of basal cell hyperplasia or stem cell clusters. We also evaluated expression of Tak1 in all grafts by using immunohistochemistry and immunoblot probed with Tak1. As expected, expression of Tak1 was diminished in grafts formed by shTak1 cells compared with grafts formed by shControl cells (Fig. 6A and B) . Moreover, activation of p38 and JNK was demonstrated to be attenuated in the grafts containing shTak1 cells compared with shControl grafts, which was consistent with the in vitro results that activation of JNK was decreased in shTak1 cells when treated with TNFĮ (Fig. 3E) . 
Suppression of Tak1 Increases Cell Proliferation In Vivo
We measured in vivo cell proliferation in shControl or shTak1 grafts by Ki67 staining. We found that cell proliferation was increased between areas of benign glands, PIN and invasive carcinoma in shTak1 grafts (Fig. 7A and B) . In vitro, we observed that suppression or loss of Tak1 increased cell proliferation in both monolayer and clonogenic growth conditions (Fig 2C,   D and F) . Therefore we compared cell proliferation by Ki67 staining in all benign regions from shControl and shTak1 grafts. Ki67 staining demonstrated a significant increase in proliferation in vivo by suppression of Tak1 (Fig. 7C and D ). These data demonstrate that suppression of Importantly, these studies establish a paradigm to functionally model putative prostate cancer genes using an in vitro/in vivo prostate developmental model.
Previous work by our group demonstrated somatic loss of 6q15.1 in human prostate cancer at rates approaching 40% (2). The loss of 6q15.1 was the most prevalent deletion in the genome.
In addition, ≅ 70% of high-grade cancers showed loss of one copy. These studies suggested the presence of a tumor suppressor at this locus. Of the five genes in the locus of the consensus deletion, Map3k7 and Casp8ap2 were the only ones expressed in our mouse prostate stem cells. The lack of expression of the other three is consistent with previous literature.
CASP8AP2, Caspase 8 associated protein 2 (also known as FLASH), was identified as a homolog of the C elegans CED-4 protein (the mammalian ortholog of CED-4 is Apaf-1).
CASP8AP2 was originally described as a proapoptotic activator of caspase 8 (29) . However, subsequent work has raised doubts about whether this protein is proapoptotic (30, 31) . Given the contradictory findings on the role of FLASH in apoptosis, our studies focused on Tak1, encoded by MAP3K7, as the most likely tumor suppressor at this locus. 
NFκB activation and modulation of NEMO activity (33) . Further work is needed to elucidate the role of Tak1 loss in these processes in prostate cancer.
Interestingly, loss of Tak1 expression in and of itself is sufficient to promote changes in morphology and invasion in vitro. These observed functions of Tak1 are not previously described and imply a basal role of Tak1 in the maintenance of a differentiated epithelial phenotype. In addition, this study demonstrates the utility of stem cell models to functionally validate prostate tumor suppressors, and by extension prostate oncogenes. Until recently, previous models relied on intact transgenic or knockout mice for specific target evaluation.
These studies have been extremely informative and have validated such targets as c-myc (34), Pten (35), Nkx3.1 (36) and p27 (37) . However, these models are time consuming, expensive, and become exponentially cumbersome when interrogating gene-gene and epithelial/mesenchymal interactions. The model described here is; 1) rapid ≅ 6 months from target identification to in vitro gene manipulation and in vitro/in vivo functional analysis; 2) comparatively inexpensive; and 3) uniquely suited for interrogating interactions between genes and tissue compartments. Primary isolation of mouse prostate stem cells by cell sorting has recently been used to evaluate the functional roles of stem cells in prostate tumor progression (38) . Recently prostate stem cell models have been used as powerful screening tools to interrogate the functional role of putative prostate cancer genes (39) (40) (41) .
In summary, we describe MAP3K7 as a prostate cancer tumor suppressor gene whose encoded protein, Tak1, has important roles in proliferation and invasion. We also describe the utility of a prostate developmental model for validation of prostate cancer genes. 
